

Hepatitis

Diseases and Vaccines

Maine Immunization Program

317 Adult Vaccines

January 2024



Agenda

- Hepatitis A and B overview – MIP
- Havrix and Twinrix – GSK (via MIP)
- Perinatal Hepatitis B – Kristin Poulin, MIP
- Heplisav-B – A.J. Fernandez, Dynavax
- Questions



Viral Hepatitis Overview

Types of Hepatitis

	A	B	C	D	E
Source	Feces	Blood/body fluids	Blood/body fluids	Blood/body fluids	Feces
Transmission	Fecal-oral	Percutaneous per mucosal	Percutaneous per mucosal	Percutaneous per mucosal	Fecal-oral
Chronic infection?	No	Yes	Yes	Yes	No
Prevention	Pre/post-exposure immunization; ensure safe food and drinking water	Pre/post-exposure immunization; risk behavior modification	Blood donor screening; risk behavior modification	Pre/post-exposure immunization against HBV; risk behavior modification	Ensure safe food and drinking water
Vaccine?	Yes	Yes	No	No*	No

*Dependent on hepatitis B virus (HBV) for replication. Vaccine against hepatitis B available.

Hepatitis A

- Liver disease
- Spread via person to person or contaminated food
- Can be prevented by vaccination and good personal hygiene/proper sanitation

People at increased risk for hepatitis A

- International travelers
- Men who have sex with men
- People who use or inject drugs
- People with occupational risk for exposure
- People who anticipate close personal contact with an international adoptee
- People experiencing homelessness

People at increased risk for severe disease

- People with chronic liver disease, including hepatitis B and hepatitis C
- People with HIV

**Vaccines available through 317:
Havrix and Vaqta**

Hepatitis A Vaccination Recommendations

Children

- All children aged 12–23 months
- All children and adolescents 2–18 years of age who have not previously received hepatitis A vaccine (known as “catch up” vaccination)

Additional Recommendations






- Pregnant women at risk for hepatitis A or risk for severe outcome from hepatitis A infection
- Any person who requests vaccination

Hepatitis A Vaccinations

Havrix

Havrix Overview

Havrix (Hepatitis A Vaccine) (GSK)¹

 <p>Type of vaccine</p>	<p>Inactivated Hepatitis A vaccine</p>
 <p>Administration</p>	<p>For intramuscular administration</p>
 <p>Indications and usage</p>	<p>Havrix is indicated for active immunization against disease caused by hepatitis A virus</p>
 <p>Dosing schedule and contraindications</p>	<p>Dosing Schedule:</p> <ul style="list-style-type: none"> > Children and Adolescents (≥ 12 months through 18 years): A single 0.5-mL dose and a 0.5-mL booster dose administered between 6 to 12 months > Adults (≥ 19 years of age): A single 1-mL dose and a 1-mL booster dose administered between 6 to 12 months later <p>Contraindications: Severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis A-containing vaccine, or any component of Havrix including neomycin.</p>
 <p>Storage</p>	<p>Refrigerated between 2°C and 8°C (36°F and 46°F)</p>



Hepatitis A Vaccinations

Havrix



GSK Hepatitis A Vaccine

Pediatric



Adult



HAVRIX®¹

HAVRIX is indicated for active immunization against disease caused by hepatitis A virus (HAV). HAVRIX is approved for use in persons 12 months of age and older. Primary immunization should be administered at least 2 weeks prior to expected exposure to HAV.

1. Prescribing Information for Havrix.

Hepatitis A Vaccinations

Vaqta



MERCK

VAQTA®


**(HEPATITIS A VACCINE,
INACTIVATED)**



Demonstrated efficacy* of
99.9% in clinical studies^{a,c}



99.4% seropositivity at 6
years^{b,d}




Flexible dosing
schedule

Hepatitis A Vaccinations

Havrix and Vaqta

	HAVRIX (Hepatitis A Vaccine) (GSK) ¹	VAQTA (Merck) ²
INDICATION AND USAGE	<p>Havrix is a vaccine indicated for active immunization against disease caused by hepatitis A virus (HAV). Havrix is approved for use in persons 12 month of age and older.</p> <p>Primary immunization should be administered at least 2 weeks prior to expected exposure to HAV.</p>	<p>Vaqta is a vaccine indicated for the prevention of disease caused by hepatitis A virus in persons 12 months of age and older.</p> <p>The primary dose should be given at least 2 weeks prior to expected exposure to HAV.</p>
DOSAGE AND ADMINISTRATION	<p>Havrix is administered by intramuscular injection</p> <ul style="list-style-type: none"> ➤ <u>Children and Adolescents:</u> A single 0.5-mL dose and a 0.5-mL booster dose administered between 6 to 12 months later ➤ <u>Adults:</u> A single 1-mL dose and a 1-mL booster dose administered between 6 to 12 months later 	<p>For intramuscular administration only</p> <ul style="list-style-type: none"> ➤ <u>Children/Adolescents:</u> vaccination consists of a 0.5-mL primary dose administered intramuscularly, and a 0.5-mL booster dose administered intramuscularly 6 to 18 months later ➤ <u>Adults:</u> vaccination consists of a 1-mL primary dose administered intramuscularly, and a 1-mL booster dose administered intramuscularly 6 to 18 months later



Hepatitis B

- Liver infection
- Spread when blood, semen, or other body fluids from an infected person
 - Examples: sexual contact; sharing needles, syringes, or other drug-injection equipment; or during pregnancy or delivery.
- Short-term illness for most
- Could become a long-term, chronic infection that can lead to serious, even life-threatening health issues.
- Age Matters
 - The younger a person is when infected with the hepatitis B virus, the greater the chance of developing chronic infection. c infection.
- Best prevention is vaccination!

**Vaccines available through 317:
Hepelisav-B**

Hepatitis B Recommendations

All adults aged 18-59 should receive the vaccine and any adult who requests it may get the vaccine

All adults 18 years and older should get screened at least once in their lifetime.

Hepatitis A and B Vaccination Twinrix



Type of vaccine

Inactivated Hepatitis A and Hepatitis B Recombinant adjuvanted vaccine



Administration

For intramuscular administration



Indications and usage

Twinrix is indicated for active immunization against disease caused by hepatitis A virus and infection by all known subtypes of hepatitis B virus. Twinrix is approved for use in persons 18 years of age or older.



Dosing schedule and contraindications

Dosing Schedule:

- > Standard Dosing: A series of 3 doses (1 mL each) given on a 0-, 1-, and 6-month schedule.
- > Accelerated Dosing: A series of 4 doses (1-mL each) given on Days 0, 7, and 21 to 30 followed by a booster dose at month 12.

Contraindications: Severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis A-containing or hepatitis-containing vaccine, or any component of Twinrix including yeast and neomycin.



Storage

Refrigerated between 2°C and 8°C (36°F and 46°F)



TWINRIX[®]3

TWINRIX is indicated for active immunization against disease caused by hepatitis A virus and infection by all known subtypes of hepatitis B virus. TWINRIX is approved for use in persons 18 years of age or older.

FOR REACTIVE USE ONLY

Kristin Poulin Perinatal Hep B Coordinator



AJ Fernandez, PharmD Medical Science Liaison



Questions?

Maine Immunization Program **MEAdultVaccine@Maine.gov**



Maine Department of Health and Human Services
Center for Disease Control and Prevention